Acorda Therapeutics Receives L.W. Freeman Award for Scientific Research; NSCIA Recognizes Acorda's Significant Contributions in Spinal Cord Injury Research.Business Editors & Health/Medical Writers BIOWIRE2K NSCIA NSCIA National Spinal Cord Injury Association NSCIA Nigerian Supreme Council for Islamic Affairs 2002 Annual Conference HAWTHORNE, N.Y. & MESA, Ariz.--(BUSINESS WIRE)--Nov. 13, 2002 Acorda Therapeutics, a biotechnology company located in Hawthorne, N.Y., will receive the L.W. Freeman Award for Scientific Research tomorrow evening at the National Spinal Cord Injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. Association (NSCIA) 2002 Annual Conference in Mesa, Ariz. This award is given annually for pioneering research on regeneration in spinal cord injury or disease and was established in memory of Dr. L. W. Freeman, who was one of the original members of the NSCIA Medical Advisory Committee. A scientist at Indiana University Indiana University, main campus at Bloomington; state supported; coeducational; chartered 1820 as a seminary, opened 1824. It became a college in 1828 and a university in 1838. The medical center (run jointly with Purdue Univ. , Dr. Freeman was committed to research that advanced the knowledge of treatment for spinal cord injury. Dr. Freeman was a tireless researcher and teacher, and he served as a key advisor to the Association until his death in 1969. Marcie Roth, executive director of the NSCIA, said, "The NSCIA recognizes the significant contribution that Acorda Therapeutics is making in scientific research that benefits the spinal cord injury community. Acorda's research platform encompasses a broad range of therapeutic targets ranging from regenerative therapies to therapies focused on improved function designed to improve the quality of life and overall health for persons living with a spinal cord injury." Ron Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. , M.D., founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Acorda Therapeutics, said, "Acorda is the first company to focus on the development of therapies to restore function in people with SCI (Scalable Coherent Interface) An IEEE standard for a high-speed bus that uses wire or fiber-optic cable. It can transfer data up to 1GBytes/sec. (hardware) SCI - 1. Scalable Coherent Interface. 2. UART. . We are proud to be working with the NSCIA to achieve this and are honored to accept this award. Our lead product, Fampridine-SR, entered Phase 3 clinical trials phase 3 clinical trial Phase 3 study. See Phase study. for chronic SCI this year. This is the first time a therapy for improving function in chronic SCI has reached that milestone. Our relationship with the NSCIA continues to be an important catalyst in helping to move the research and education forward in SCI." The awards ceremony will take place at The Sheraton Mesa Hotel and Convention Center at 6:00 pm on Thursday, Nov. 14, 2002. Elliott Gruskin, Ph.D., vice president of Research & Development for Acorda, will accept the award on behalf of the company. About the NSCIA The National Spinal Cord Injury Association, founded in 1948, is the nation's oldest and largest civilian organization dedicated to improving the quality of life and opportunities for the hundreds of thousands of Americans living with the results of spinal cord injury and disease (SCI/D) and their families. This number grows by 30 newly-injury people each day. About Acorda Therapeutics Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury and related neurological conditions Neurological conditions A condition that has its origin in some part of the patient's nervous system. Mentioned in: Pervasive Developmental Disorders , including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and is in Phase 2 trials for MS. Acorda's technology platform also includes a class of human monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). that have been shown to remyelinate the central nervous system in animal models. These antibodies are in preclinical development for MS. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord spinal cord, the part of the nervous system occupying the hollow interior (vertebral canal) of the series of vertebrae that form the spinal column, technically known as the vertebral column. and brain. Interview Opportunities: -- Ron Cohen, M.D., CEO, Acorda Therapeutics -- Elliott Gruskin, Ph.D., vice president of R&D, Acorda Therapeutics -- Marcie Roth, executive director, National Spinal Cord Injury Association, Phone: 301/717-7447 Fax: 301/588-6959 E-mail: mroth@spinalcord.org |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion